Foxo technologies announces issue notification from uspto for a patent leveraging machine learning approaches to enable the commercialization of epigenetic biomarkers

Minneapolis--(business wire)--foxo technologies inc. (nyse american: foxo) (“foxo” or the “company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that the united states patent & trademark office (uspto) has provided an issue notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using dna epigenetic data to enable the commercialization of epigenetic biomarkers. previousl.
FOXO Ratings Summary
FOXO Quant Ranking